Incyte Corporation
Rank #41HypergrowthINCY · Nasdaq · Healthcare
Incyte Corporation (INCY) — Rank #41 by gross profitability (GP/assets 0.65) · ROE 22.9% · Piotroski F-Score N/A.
As-of 2026-09-28 · CIK 0000879169 · all metrics point-in-time as of the filing date.
About
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Show moreShow less
The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- incyte.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilityimproving
- Net cashstable
- Operating marginstable
- Return on equitydeteriorating
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-10 | 2024-12-31filed 2025-02-10 | 2023-12-31filed 2024-02-13 | 2022-12-31filed 2023-02-07 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 5,141.2 | 4,241.2 | 3,695.6 | 3,394.6 |
| Revenue growth (YoY) | 21.2% | 14.8% | 8.9% | 13.7% |
| Gross profit | 4,769.1 | 3,929.1 | 3,440.7 | 3,187.6 |
| Gross margin | 92.8% | 92.6% | 93.1% | 93.9% |
| Net income | 1,286.7 | 32.6 | 597.6 | 340.7 |
| Net margin | 25.0% | 0.8% | 16.2% | 10.0% |
| EPS (diluted) | $6.41 | $0.15 | $2.65 | $1.52 |
| EPS growth (YoY) | 4173.3% | -94.3% | 74.3% | — |
| Cash flow | ||||
| Operating cash flow | 1,413.5 | 335.3 | 496.5 | 969.9 |
| Capital expenditures | 58.9 | 86.3 | — | 77.8 |
| Free cash flow | 1,354.6 | 249.1 | — | 892.1 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?